literature

HIV mutation literature information.

Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

PMID: 22900472 2013 AIDS research and human retroviruses

Abstract: Two TDR mutations to nucleoside reverse transcriptase inhibitors [n=1 (T215D)] and protease inhibitors [n=1 (M46L)] were identified, giving an overall TDR prevalence of 1.1% (95% CI: 0.1-3.9).

Transmitted HIV type 1 drug resistance in newly diagnosed Cuban patients.

PMID: 22985307 2013 AIDS research and human retroviruses

Abstract: In the region of the reverse transcriptase, the most common mutations were K103N and M184V, while in the region of the protease they were L33F and M46L.

HIV-1 drug resistance-associated mutations among antiretroviral-naive Thai patients with chronic HIV-1 infection.

PMID: 23161095 2013 Journal of medical virology

Abstract: The only major DRAM for PIs was M46L (0.6%).

"Description of the L76V resistance protease mutation in HIV-1 B and ""non-B"" subtypes."

PMID: 23349869 2013 PloS one

5Result: Significant differences in the prevalence of

Method: In our study, samples with at least one of the major PI RAM of the IAS-USA list as follows: D30N, V32I, M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V, V82A/F/L/T/S, N83D, I84V, N88S, L90M were considered as PI-resistant issued from PI-experienced patients.

Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data.

PMID: 23436985 2013 PLoS computational biology

Figure: M46L, A71T, V82A, V82S) but also several novel mutations (e.g.

Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.

PMID: 23469241 2013 PloS one

Table: M46I/L

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).

PMID: 23585827 2013 PloS one

Result:

Table: M46L

Figure: Histogram showing number of women with drug resistant HIV infection that had each of the following protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations M46L, I85V, K65R, L74I, K219E, M184V, K101E, V106M, Y181C or G190A.

Transmitted HIV drug resistance in treatment-naive Romanian patients.

PMID: 23592112 2013 Journal of medical virology

Result: Both isolates presented the M46L mutation-conferring intermediate-level resistance to nelfinavir and potential low-level resistance to lopinavir and atazanavir-alone in the subtype C strain and along with multiple other resistance mutations, such as L24I, I47V, F53L, I54V, and V82A in the F1 strain.

Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in Spain.

PMID: 23717585 2013 PloS one

Abstract: Transmitted drug-resistance (TDR) rate among naive patients attended in Spain (n = 144) was 4.7%: 3.4% for PI (all with M46IL), 1.8% for NRTI (all with M184V) and 0.9% for NNRTI (Y188L).

Result: In 5 (3.4%) subjects, the mutations affected PR inhibitors (PI), with M46I/L substitution in all cases.

Result: The PI-resistance mutations found were M46L (4 cases), and L90M and I84V (3 cases each).

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Method: The following protease mutations were considered LPV/r-resistance mutations: L10F, L24I, V32I, L33F, M46IL, I47A, I50V, I54MLV, L76V, V82ATSFMC, I84V, L89V, L90M.

Table: M46I/L

Table: M46L

Browser Board

Co-occurred Entities

Filtrator